Surgery for Mesothelioma

For carefully selected patients, surgery offers the best chance for long-term survival. Understanding the different surgical options, their risks and benefits, and whether you might be a candidate can help you make informed decisions about your treatment.

Advanced medical research facility with modern surgical planning technology
Surgical advances and careful patient selection improve outcomes for mesothelioma surgery

Goals of Mesothelioma Surgery

Surgical treatment of mesothelioma serves different purposes depending on the patient's situation:

Radical Surgery (Potentially Curative)

  • Goal: Remove all visible tumor (macroscopic complete resection)
  • Best candidates: Early-stage disease, epithelioid cell type, good overall health
  • Combined with: Chemotherapy and/or radiation (multimodal therapy)
  • Hope for: Extended survival and possible cure

Palliative Surgery

  • Goal: Relieve symptoms and improve quality of life
  • Procedures: Fluid drainage, pleurodesis, tumor debulking
  • Benefits: Easier breathing, reduced pain
  • No attempt: To remove all cancer

Pleural Mesothelioma Surgery

For pleural mesothelioma (lung lining), two main radical surgical options exist:

1. Extrapleural Pneumonectomy (EPP)

Extrapleural pneumonectomy (EPP) is the most extensive surgery for pleural mesothelioma:

What Is Removed:

  • The affected lung
  • The pleura (lining of the chest cavity and lung)
  • Part or all of the diaphragm
  • The pericardium (heart sac)
  • Nearby lymph nodes

The diaphragm and pericardium are reconstructed with surgical mesh.

Candidacy Requirements:

  • Stage 1-2 disease (confined to one side of chest)
  • Epithelioid or mixed cell type
  • Good heart function
  • Strong remaining lung (FEV1 > 40% predicted)
  • No spread to distant organs
  • Good overall health and performance status

Benefits:

  • Most complete tumor removal possible
  • May allow higher-dose radiation to affected side
  • Best chance for long-term survival in selected patients

Risks and Drawbacks:

  • High perioperative mortality (3-6%)
  • Significant morbidity
  • Permanent loss of one lung
  • Long recovery period
  • Cannot be repeated if recurrence

Survival:

  • Median survival: 12-22 months with multimodal therapy
  • Selected patients: 3-5+ years
  • 5-year survival: 10-15% in optimal candidates

2. Pleurectomy/Decortication (P/D)

Pleurectomy/decortication (P/D) removes the pleura and visible tumors while sparing the lung:

What Is Done:

  • Removal of the parietal pleura (chest wall lining)
  • Removal of the visceral pleura (lung lining)
  • Removal of visible tumor nodules from lung surface
  • May include diaphragm or pericardium if involved

Types of P/D:

  • Extended P/D: Includes diaphragm and/or pericardium
  • Partial P/D: Less extensive, rarely used today

Benefits:

  • Lung is preserved
  • Lower mortality than EPP (1-2%)
  • Better quality of life post-surgery
  • Can be repeated if local recurrence
  • Suitable for more patients

Drawbacks:

  • May leave microscopic disease on lung
  • Cannot receive high-dose radiation to preserved lung
  • May require repeat procedures

Survival:

  • Similar or better than EPP in many studies
  • Median survival: 16-30 months
  • 5-year survival: 15-20%

EPP vs. P/D: Which Is Better?

This is a subject of ongoing debate among surgeons:

Factor EPP P/D
Mortality 3-6% 1-2%
Complications Higher Lower
Quality of life More impairment Better preserved
Complete removal More likely May leave residual
Eligibility Stricter criteria More inclusive
Survival Similar in matched patients Similar or better

Many experts now favor P/D when technically feasible, as survival appears equivalent with less morbidity.

Peritoneal Mesothelioma Surgery

For peritoneal mesothelioma (abdominal lining), the standard surgical approach is:

Cytoreductive Surgery (CRS) with HIPEC

This combination has transformed outcomes for peritoneal mesothelioma:

The Procedure:

  1. Cytoreductive surgery: Removal of all visible tumors in the abdomen
    • May remove parts of organs if involved
    • Goal is complete macroscopic removal (CC-0 or CC-1)
    • Can take 8-14 hours
  2. HIPEC: Heated intraperitoneal chemotherapy
    • Heated chemotherapy circulated in abdomen
    • Heat improves drug penetration
    • Direct contact kills remaining cells
    • Lasts 60-90 minutes

Outcomes:

  • Median survival: 3-7 years (vs. 12 months without surgery)
  • 5-year survival: 30-50%
  • Some patients: Long-term survivors 10+ years

Requirements:

  • Complete or near-complete cytoreduction possible
  • No extensive small bowel involvement
  • No distant metastases
  • Good overall health

Recovery After Surgery

Proper post-surgery care is essential for optimal recovery and managing complications. Physical therapy plays a critical role in rehabilitation, and therapeutic exercise can help restore strength and function.

Hospital Stay:

  • EPP: 10-14 days
  • P/D: 7-10 days
  • CRS/HIPEC: 10-21 days

Recovery Timeline:

Potential Complications:

  • Infection
  • Bleeding
  • Blood clots
  • Respiratory complications
  • Heart problems (after EPP)
  • Nutritional issues (after HIPEC)

Is Surgery Right for You?

Questions to Discuss With Your Doctor:

  • Am I a candidate for surgery based on my stage and cell type?
  • Which procedure do you recommend and why?
  • What are the risks specific to my situation?
  • What is your experience with this surgery?
  • What are realistic expectations for recovery and survival?
  • What is the role of chemotherapy and radiation?

Second Opinions Are Essential:

Surgical decisions are among the most important in mesothelioma treatment. Seeking opinions from experienced mesothelioma surgeons at high-volume centers is strongly recommended.

👨‍⚕️

Medically Reviewed

Dr. Emily Carter, MD

Board-Certified Medical Oncologist specializing in thoracic cancers

Last reviewed: March 2026

Sources & References

  1. Flores RM, et al. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication in the Surgical Management of Malignant Pleural Mesothelioma: Results in 663 Patients. J Thorac Cardiovasc Surg. 2008;135(3):620-626
  2. NCCN Guidelines: Malignant Pleural Mesothelioma - Surgery
  3. NCI: Surgery for Mesothelioma

Candidacy for Mesothelioma Surgery

Not all mesothelioma patients are candidates for curative-intent surgery. Eligibility depends on several factors that surgeons evaluate carefully before recommending a procedure. The stage of the cancer is the most important consideration: surgery is typically most effective for patients diagnosed at stage 1 or stage 2, when the cancer is still relatively localized. For patients with more advanced disease (stage 3 or stage 4), surgery may still play a role in managing symptoms but is less likely to significantly extend survival.

The histological cell type also influences surgical candidacy. Patients with epithelioid mesothelioma, the most common cell type, tend to respond better to surgery than those with sarcomatoid or biphasic subtypes. Epithelioid cells grow more slowly and are less likely to have spread beyond the surgical field. The patient's overall health, lung function, and cardiac status are assessed through pulmonary function tests, cardiac stress tests, and imaging studies to determine whether they can safely undergo and recover from major thoracic surgery.

Multimodal Treatment Approaches

Surgery for mesothelioma is rarely performed as a standalone treatment. The most effective approaches combine surgery with chemotherapy and sometimes radiation therapy in what is known as multimodal treatment. The specific combination and sequence of therapies varies based on the patient's individual circumstances and the treatment center's protocols.

Neoadjuvant chemotherapy (given before surgery) aims to shrink the tumor and make surgical removal more complete. The standard regimen combines pemetrexed with cisplatin or carboplatin, typically administered for 3-4 cycles over several months. Studies have shown that patients who respond to neoadjuvant chemotherapy tend to have better surgical outcomes and longer survival times.

Adjuvant therapy (given after surgery) may include radiation therapy to the surgical site, additional chemotherapy cycles, or both. Intensity-modulated radiation therapy (IMRT) can target the areas where cancer is most likely to recur while minimizing damage to surrounding healthy tissue. Some centers are also investigating the role of immunotherapy as an adjuvant treatment following surgery.

Recovery and Follow-Up After Surgery

Recovery from mesothelioma surgery varies depending on the extent of the procedure performed. An extrapleural pneumonectomy (EPP), which removes an entire lung along with the surrounding pleura, pericardium, and diaphragm, requires a hospital stay of approximately 7-14 days and a recovery period of several weeks to months. A pleurectomy with decortication (P/D), which preserves the lung while removing the diseased pleura, generally has a shorter recovery period because lung function is maintained.

Following surgery, patients undergo regular follow-up imaging—typically CT scans every 3-4 months for the first two years—to monitor for recurrence. Pulmonary rehabilitation may be recommended to help rebuild lung capacity and physical endurance. Pain management is an important aspect of recovery, as thoracic surgery can cause significant post-operative discomfort that may persist for weeks.

Surgical Options for Peritoneal Mesothelioma

For peritoneal mesothelioma, the primary surgical approach is cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). During this procedure, the surgeon removes all visible tumor tissue from the abdominal cavity and peritoneal surfaces—a process that may involve removing portions of the peritoneum, omentum, and affected organ surfaces. After tumor removal, heated chemotherapy (typically mitomycin C, cisplatin, or a combination) is circulated directly through the abdominal cavity for 60-90 minutes before the abdomen is closed.

The CRS-HIPEC approach has significantly improved outcomes for peritoneal mesothelioma patients. Studies have reported median survival times of 3-5 years for patients who undergo complete cytoreduction, with some patients surviving 10 years or longer. The completeness of cytoreduction is the most important predictor of long-term survival—patients in whom all visible tumor can be removed have substantially better outcomes than those with residual disease. Not all patients are candidates for this procedure; eligibility depends on the extent of disease, cell type, absence of distant metastases, and the patient's overall fitness for a lengthy operation.